Biograil Secures Seed 2 Funding for Oral Delivery Device for Biologics
Biograil ApS, a Copenhagen based biotech startup developing a unique oral device for delivery of biologics that would otherwise be injected, announced the closing of a Seed 2 funding of 3.2 million Euro. The Round was led by Danish Megatrend Invest a/s with strong support from other prior investors including Verve Ventures, a Swiss Investment group and Sanner Ventures, a German family office. Evonik Venture Capital participated as a new investor.

Symbolic image
Unsplash/pixabay.com
Evonik Venture Capital is the corporate venture capital arm of Evonik Industries, one of the world leaders in specialty chemicals. Evonik has in-depth understanding of biodegradable polymers in pharma and medical device applications and will support the company efforts to create a fully biodegradable and environmentally friendly delivery solution which provides additional strategic value to Biograil.
"Biograil is very pleased with the strong internal support and commitment from current ownership and great to see that we continue to be able to attract new experienced investors like Evonik Venture Capital to our Investor Syndicate. We look forward to the technical support Evonik can provide to identify and/or potentially develop suitable biodegradable polymers for our capsule technology and our strive to make BIONDDTM the preferred oral delivery device technology for peptides and biomacromolecules", Karsten Lindhardt, Biograil CEO.
"Evonik Venture Capital is glad to now be part of the Biograil Investor Syndicate. We see a large business potential for oral drug delivery devices. The BIONDDTM technology and team behind Biograil has a great opportunity to develop an excellent technical solution to the future benefit of patients. We look forward to provide our expertise in biodegradable polymers to support the Biograil team and their efforts to further progress this platform technology", Jonas Ide, Investment Manager at Evonik Venture Capital (now an observer in the Board of Directors of Biograil).
Biograil will use the funds to optimize the design of its delivery device and to advance its ongoing preclinical testing and initiate preparation for development activities and to plan for substantial investment and collaboration funding in 2022 to further transition the company from research to a development stage company.
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
More news from our other portals
Something is happening in the life science industry ...
This is what true pioneering spirit looks like: Plenty of innovative start-ups are bringing fresh ideas, lifeblood and entrepreneurial spirit to change tomorrow's world for the better. Immerse yourself in the world of these young companies and take the opportunity to get in touch with the founders.
Last viewed contents

Artificial intelligence, hardware innovations boost confocal microscope’s performance - Enhancing the workhorse
Anemia: Baffling lab mystery leads to major red blood cell discovery
BioPhausia focuses and sells OTC products to Meda for SEK 190 million
The Biotechnology Industry over 30 Billion in Revenue - ASEBIO presented its annual report "Informe ASEBIO 2009"

Vitamin B6 may help keep COVID-19's cytokine storms at bay - Vitamin B6 may help calm cytokine storms and unclog blood clots linked to COVID-19's lethality

Born to break - Mutation causes fragile bones

"Dormant" magnetosome genes in non-magnetic bacteria discovered

How injured nerves stop themselves from healing - Researchers have discovered an unexpected effect: It might open up new avenues for developing therapies after brain or spinal cord damage
Scil Proteins Signs Research Collaboration with the Martin Luther University Halle-Wittenberg for Gastrointestinal Tumors
Cotton fibres instead of carbon nanotubes

3D-printed pills with desired drug release – a step upwards in medication - Funny looking pills are not a design gimmick, they can release medication in a desired time regime!
